2020
Insights into Cognitive Disorders in Aging and Mental Illness: Molecular Influences on Circuits of the Prefrontal Cortex
Arnsten A. Insights into Cognitive Disorders in Aging and Mental Illness: Molecular Influences on Circuits of the Prefrontal Cortex. 2020 DOI: 10.1093/oxfordhb/9780190069162.013.4.Peer-Reviewed Original ResearchPrefrontal cortexAbsence of sensory stimulationGoal-directed behaviorTop-down controlWorking memoryPrefrontal microcircuitsAffective disordersDynamic network connectivityMental disordersArousal systemCognitive disordersMental illnessCortical synaptic connectivityAbstract thoughtCortexRepresentation of informationDisordersSensory stimulationSynaptic strengthAlzheimer's diseaseRecurrent excitatory connectionsSynaptic connectionsExcitatory connectionsSchizophreniaNetwork connectivity
2014
Catecholamine influences on prefrontal cortex circuits and function
Arnsten A, Berridge C. Catecholamine influences on prefrontal cortex circuits and function. 2014, 161-173. DOI: 10.1017/cbo9781139035491.015.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderHyperactivity disorderManagement of ADHDDiagnosis of ADHDChronic neurobehavioral disorderPrefrontal cortex circuitCatecholamine influenceCortex circuitTreatment modalitiesPsychiatric illnessNeurobehavioral disordersClinical optionBipolar disorderSocial workersDisordersRecent researchDiagnosisAdultsChildrenDevelopmental processesDistractibilityImpulsivityPsychologistsComorbiditiesWorld-renowned expertsGuanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents
Connor DF, Arnsten A, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opinion On Pharmacotherapy 2014, 15: 1601-1610. PMID: 24992513, DOI: 10.1517/14656566.2014.930437.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderHyperactivity disorderSymptoms of ADHDEvidence-based treatmentsTraumatic stressBehavioral dysregulationADHD studiesSmall effect sizesPrefrontal cortexAdolescents 6Behavioral conditionsAdolescentsEffect sizeGXRPsycINFO databasesGuanfacinePsychostimulantsShire PharmaceuticalsOpen trialChildrenPotential promiseSecond-line treatmentDisordersAntihypertensive agentsAdrenoreceptor agonist
2012
Attention deficit hyperactivity disorder
Berridge C, Devilbiss D, Spencer R, Schmeichel B, Arnsten A. Attention deficit hyperactivity disorder. 2012, 303-320. DOI: 10.1017/cbo9780511980053.018.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderHyperactivity disorderNeurodevelopmental disordersMore effective treatmentsMultiple sclerosisDisease groupEffective treatmentParkinson's diseaseBipolar disorderBrain disordersAlzheimer's diseaseClinical advancementTranslational neuroscienceSubstance abuseDiseaseDisordersField of psychiatryPublic healthCliniciansNeurologyPsychiatryPainSclerosisEpilepsyGuanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. The Yale Journal Of Biology And Medicine 2012, 85: 45-58. PMID: 22461743, PMCID: PMC3313539.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPrefrontal cortexCognitive disordersHigher-order cognitive abilitiesDeficit hyperactivity disorderPFC cognitive functionCognitive abilitiesHyperactivity disorderCognitive functionMemory functionPFC functionAgonist guanfacineBrain regionsGuanfacineRecent researchNeurobiologyYale Medical SchoolCentury of discoveryDisordersTherapeutic targetTourette syndromePostsynaptic spinesEmotionsMemorySyndrome
2010
The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder
Arnsten A. The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review Of Neurotherapeutics 2010, 10: 1595-1605. PMID: 20925474, PMCID: PMC3143019, DOI: 10.1586/ern.10.133.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderPrefrontal cortexHyperactivity disorderPFC functionPFC gray matterPFC pyramidal cellsPyramidal cell networksDorsolateral prefrontal cortexPFC connectionsReceptors inhibitsPyramidal cellsAdrenergic agonistsDendritic spinesVentromedial prefrontal cortexGray matterRelated disordersBrain regionsNeuropsychiatric disordersPotassium channelsDisordersPatientsRecent dataPhysiological connectionTreatmentExecutive functioning
2008
Pharmacologic approaches to cognitive rehabilitation
McAllister T, Arnsten A. Pharmacologic approaches to cognitive rehabilitation. 2008, 298-320. DOI: 10.1017/cbo9781316529898.022.Peer-Reviewed Original ResearchCognitive rehabilitationCognitive neuroscienceCognitive changesEfficacy of interventionsVariety of populationsSuccessful interventionsRehabilitation successDifferent disordersNeuroscienceInterventionRehabilitationMemoryExternal factorsRole of imagingLanguagePharmacologic approachesDisordersNew findingsLatest developmentsClinical applicationPractical guidanceFindingsResearchEdition
2007
Norepinephrine and cognitive disorders
Arnsten A. Norepinephrine and cognitive disorders. 2007, 408-435. DOI: 10.1017/cbo9780511544156.015.Peer-Reviewed Original ResearchNoradrenergic drugsCentral nervous system norepinephrineNervous system norepinephrineRole of norepinephrineNoradrenergic neuronsCNS diseaseTherapeutic effectCognitive disordersNorepinephrineNeurological disordersNorepinephrine's roleBrain diseasesNew disease indicationsChemical neurotransmittersDisease indicationsDrugsDiseasePharmacologyDisordersTherapeuticsBasic biologyMolecular biologyNeurotransmittersNeuronsBrain
2006
Estrogen enhances stress-induced prefrontal cortex dysfunction: relevance to Major Depressive Disorder in women
Shansky R, Arnsten A. Estrogen enhances stress-induced prefrontal cortex dysfunction: relevance to Major Depressive Disorder in women. Dialogues In Clinical Neuroscience 2006, 8: 478-481. PMCID: PMC3181833.Peer-Reviewed Original ResearchMajor depressive disorderPost-traumatic stress disorderDepressive disorderPrevalence of MDDPrefrontal cortex dysfunctionMost anxiety disordersAnimal modelsMental illnessBrain regionsEstrogenStress disorderAnxiety disordersNeurobiological responsesWomenDisordersEffects of stressLiterature demonstratingMenGreater vulnerabilityBiological causesDysfunctionIllnessPrevalenceStress responseBrain
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment
2002
Neurobiology of attention regulation and its disorders
Arnsten A, Castellanos F. Neurobiology of attention regulation and its disorders. 2002, 99-109. DOI: 10.1093/oso/9780195141733.003.0008.Peer-Reviewed Original ResearchAttentional processesAspects of attentionRegulation of attentionDissociable neural processesAttentional resourcesAttention regulationWord attentionNeural processesAttention disordersCortical mechanismsBrain networksInternal stimuliStimuliAttentionDisordersExternal stimuliArousalComplex waysMemorySalienceGood reasonComplicating mattersNeurobiologyMotivationAdjectives
2000
Dopaminergic and Noradrenergic Influences on Cognitive Functions Mediated by Prefrontal Cortex
Arnsten A. Dopaminergic and Noradrenergic Influences on Cognitive Functions Mediated by Prefrontal Cortex. 2000, 185-208. DOI: 10.1093/oso/9780195133714.003.0008.Peer-Reviewed Original Research
1999
α-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function
Arnsten A, Mathew R, Ubriani R, Taylor J, Li B. α-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biological Psychiatry 1999, 45: 26-31. PMID: 9894572, DOI: 10.1016/s0006-3223(98)00296-0.Peer-Reviewed Original ResearchConceptsPrefrontal cortexCognitive functionPrefrontal cortical cognitive functionCortical cognitive functionsImpairs cognitive functionHigher cortical functionsMemory taskAlpha-1 adrenoceptorsMost antipsychotic medicationsAlternation performanceNoradrenergic turnoverCortical functionPhenylephrine responseAlpha-1 adrenoceptor stimulationNeuropsychiatric disordersAlpha-1 adrenergic antagonistAlpha-1 adrenergic agonistDisordersAntipsychotic medicationAnxietyHigh levelsPhenylephrine infusionAdrenoceptor stimulationAdrenergic antagonistsSecond messenger pathways
1998
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten A. Catecholamine modulation of prefrontal cortical cognitive function. Trends In Cognitive Sciences 1998, 2: 436-447. PMID: 21227275, DOI: 10.1016/s1364-6613(98)01240-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPrefrontal cortexCognitive functionPrefrontal cortical cognitive functionUncontrollable stressCortical cognitive functionsWorking Memory FunctionDeficit hyperactivity disorderHyperactivity disorderPFC functionPFC dysfunctionNormal agingCognitive disordersCatecholamine modulationDopamine systemNeurochemical influencesMental disordersNeuropsychiatric disordersDisordersEnvironmental cuesCuesNeuromodulatory inputsMemoryFresh understandingHigh levels